HK1217457A1 - 病毒複製抑制劑、它們的製備方法和它們的治療用途 - Google Patents
病毒複製抑制劑、它們的製備方法和它們的治療用途Info
- Publication number
- HK1217457A1 HK1217457A1 HK16105334.6A HK16105334A HK1217457A1 HK 1217457 A1 HK1217457 A1 HK 1217457A1 HK 16105334 A HK16105334 A HK 16105334A HK 1217457 A1 HK1217457 A1 HK 1217457A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- inhibitors
- preparation
- viral replication
- therapeutical uses
- therapeutical
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000029812 viral genome replication Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
- C07C59/13—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups containing rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13305965.9A EP2821104A1 (en) | 2013-07-05 | 2013-07-05 | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
PCT/EP2014/064446 WO2015001125A1 (en) | 2013-07-05 | 2014-07-07 | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1217457A1 true HK1217457A1 (zh) | 2017-01-13 |
Family
ID=48793140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16105334.6A HK1217457A1 (zh) | 2013-07-05 | 2016-05-10 | 病毒複製抑制劑、它們的製備方法和它們的治療用途 |
Country Status (14)
Country | Link |
---|---|
US (1) | US9994509B2 (zh) |
EP (2) | EP2821104A1 (zh) |
JP (1) | JP6571645B2 (zh) |
KR (1) | KR20160030213A (zh) |
CN (1) | CN105492075B (zh) |
AU (1) | AU2014286074A1 (zh) |
BR (1) | BR112015032379A2 (zh) |
CA (1) | CA2916335A1 (zh) |
CL (1) | CL2015003752A1 (zh) |
ES (1) | ES2707675T3 (zh) |
HK (1) | HK1217457A1 (zh) |
MX (1) | MX364704B (zh) |
RU (1) | RU2678575C2 (zh) |
WO (1) | WO2015001125A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2772480B2 (en) † | 2011-10-25 | 2020-12-09 | Shionogi & Co., Ltd. | Hiv replication inhibitor |
EP2719685A1 (en) * | 2012-10-11 | 2014-04-16 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
CN106496008A (zh) * | 2016-10-20 | 2017-03-15 | 上海毕得医药科技有限公司 | 一种合成4‑(4‑氯苯基)环己酮的方法 |
US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2842559A (en) | 1954-10-20 | 1958-07-08 | Wisconsin Alumni Res Found | Synthesis of estrone intermediates |
GB942663A (en) | 1960-04-06 | 1963-11-27 | Director | Phenyl cyclohexane and -cyclohexene derivatives, new intermediates for the synthesis of the female sex hormone estrone and other steroids |
IL59557A (en) | 1979-03-12 | 1983-10-31 | Lilly Co Eli | 1,1-biphenyl-2-yl propyl butyl and pentyl amines,their preparation and pharmaceutical compositions comprising them |
GB8330099D0 (en) | 1983-11-11 | 1983-12-21 | Ici Plc | Cycloalkane derivatives |
US4872918A (en) | 1986-05-12 | 1989-10-10 | Philip Morris Incorporated | Heterocyclic esters and smoking compositions containing a heterocyclic ester flavorant-release additive |
FR2772761B1 (fr) | 1997-12-23 | 2000-05-26 | Lipha | Nouveaux derives de n-phenylamide et n-pyridylamide, leur procede de preparation et compositions pharmaceutiques les contenant |
CA2318184C (en) | 1998-01-21 | 2008-11-18 | Banyu Pharmaceutical Co., Ltd. | Substituted 5-(2,2-difluoro-1,3-benzodioxol-5-yl) cyclopentenopyridine derivative as selective endothelin antagonists |
FR2875805B1 (fr) | 2004-09-27 | 2006-12-29 | Genfit S A | Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations |
JP4476232B2 (ja) | 2006-03-10 | 2010-06-09 | 三菱重工業株式会社 | 成膜装置のシーズニング方法 |
JP2009530281A (ja) | 2006-03-14 | 2009-08-27 | アムジエン・インコーポレーテツド | 代謝障害の治療に有用である二環式カルボン酸誘導体 |
US7939545B2 (en) | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
US20100168225A1 (en) | 2007-04-18 | 2010-07-01 | Francois Jean | Small-Molecule Hepatitis C Virus (HCV) NS3/4A Serine Protease Inhibitors |
PT2220076E (pt) | 2007-11-15 | 2012-04-26 | Gilead Sciences Inc | Inibidores da replicação do vírus da imunodeficiência humana |
JP5269085B2 (ja) | 2007-11-15 | 2013-08-21 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルス複製のインヒビター |
ES2463720T3 (es) | 2007-11-16 | 2014-05-29 | Gilead Sciences, Inc. | Inhibidores de la replicación del virus de inmunodeficiencia humana |
WO2009062285A1 (en) | 2007-11-16 | 2009-05-22 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
RU2379049C2 (ru) * | 2007-12-11 | 2010-01-20 | Олег Витальевич Калюжин | Средство для лечения вич-инфекции |
US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
RU2011123777A (ru) | 2008-11-14 | 2012-12-20 | ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. | Бифенилацетамидные производные |
US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
GB0913636D0 (en) | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
PT2588450T (pt) | 2010-07-02 | 2017-08-03 | Gilead Sciences Inc | Derivados do ácido naft-2-ilacético para tratamento da sida |
PE20130525A1 (es) | 2010-07-02 | 2013-05-05 | Gilead Sciences Inc | Derivados de acido 2 quinolinil acetico como compuestos antivirales frente a vih |
EP2511273B8 (en) | 2011-04-15 | 2019-06-26 | Hivih | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
EP2699558B1 (en) | 2011-04-21 | 2016-11-23 | Gilead Sciences, Inc. | Benzothiazole compounds and their pharmaceutical use |
EP2772480B2 (en) | 2011-10-25 | 2020-12-09 | Shionogi & Co., Ltd. | Hiv replication inhibitor |
EP2719685A1 (en) | 2012-10-11 | 2014-04-16 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
EP2971077B1 (en) * | 2013-03-15 | 2019-05-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment and prediction of myocardial infarction |
-
2013
- 2013-07-05 EP EP13305965.9A patent/EP2821104A1/en not_active Withdrawn
-
2014
- 2014-07-07 RU RU2015155438A patent/RU2678575C2/ru not_active IP Right Cessation
- 2014-07-07 KR KR1020167002741A patent/KR20160030213A/ko not_active Application Discontinuation
- 2014-07-07 EP EP14735599.4A patent/EP3016714B1/en not_active Not-in-force
- 2014-07-07 ES ES14735599T patent/ES2707675T3/es active Active
- 2014-07-07 CN CN201480043336.4A patent/CN105492075B/zh not_active Expired - Fee Related
- 2014-07-07 CA CA2916335A patent/CA2916335A1/en not_active Abandoned
- 2014-07-07 AU AU2014286074A patent/AU2014286074A1/en not_active Abandoned
- 2014-07-07 BR BR112015032379A patent/BR112015032379A2/pt not_active IP Right Cessation
- 2014-07-07 MX MX2016000037A patent/MX364704B/es active IP Right Grant
- 2014-07-07 US US14/902,955 patent/US9994509B2/en not_active Expired - Fee Related
- 2014-07-07 JP JP2016522659A patent/JP6571645B2/ja not_active Expired - Fee Related
- 2014-07-07 WO PCT/EP2014/064446 patent/WO2015001125A1/en active Application Filing
-
2015
- 2015-12-29 CL CL2015003752A patent/CL2015003752A1/es unknown
-
2016
- 2016-05-10 HK HK16105334.6A patent/HK1217457A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP2821104A1 (en) | 2015-01-07 |
JP6571645B2 (ja) | 2019-09-04 |
US20160152543A1 (en) | 2016-06-02 |
BR112015032379A2 (pt) | 2017-07-25 |
CN105492075A (zh) | 2016-04-13 |
MX364704B (es) | 2019-05-06 |
EP3016714B1 (en) | 2018-09-19 |
WO2015001125A1 (en) | 2015-01-08 |
KR20160030213A (ko) | 2016-03-16 |
CN105492075B (zh) | 2019-11-12 |
CL2015003752A1 (es) | 2016-08-05 |
ES2707675T3 (es) | 2019-04-04 |
JP2016527211A (ja) | 2016-09-08 |
RU2015155438A (ru) | 2017-06-28 |
MX2016000037A (es) | 2016-05-31 |
US9994509B2 (en) | 2018-06-12 |
RU2015155438A3 (zh) | 2018-04-28 |
CA2916335A1 (en) | 2015-01-08 |
RU2678575C2 (ru) | 2019-01-30 |
AU2014286074A1 (en) | 2016-01-21 |
EP3016714A1 (en) | 2016-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL274720A (en) | Methods for preparing influenza virus reproduction suppressors | |
HK1219975A1 (zh) | 用於病毒生產的細胞系和使用方法 | |
ZA201307604B (en) | Inhibitors of viral replication, their process of preparation and their therapeutical uses | |
IL245213A0 (en) | Inhibitors of human immunodeficiency virus replication | |
IL237154A0 (en) | Inhibitors of human immunodeficiency virus replication | |
ZA201307442B (en) | Inhibitors of viral replication. their process of preparation and their therapeutical uses | |
PT3286166T (pt) | Inibidores de replicação do vírus da imunodeficiência humana | |
PT2814490T (pt) | Inibidores de replicação do vírus da imunodeficiência humana | |
HK1212980A1 (zh) | 吡啶酮類衍生物、其製備方法及其在醫藥上的應用 | |
LT3068776T (lt) | Gripo virusų replikacijos inhibitoriai | |
HK1213260A1 (zh) | 新型病毒複製抑制劑 | |
EP2999474A4 (en) | THERAPEUTIC AND METHOD OF USE | |
HK1209324A1 (zh) | 納米酶、製備納米酶的方法、以及使用納米酶的方法 | |
HK1211290A1 (zh) | 用於治療病毒性疾病的雜環取代四環化合物及其使用方法 | |
EP2945953A4 (en) | SUBSTITUTED TETRACYCLIC THIOPHONE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES | |
HK1217457A1 (zh) | 病毒複製抑制劑、它們的製備方法和它們的治療用途 | |
HK1216881A1 (zh) | 用於治療病毒感染和另外的疾病的吡啶酮衍生物 | |
PT3107913T (pt) | Inibidores da replicação do vírus da imunodeficiência humana | |
ZA201507212B (en) | N-haloalkylindoline intermediates, their process and use in preparation of silodosin and its derivatives | |
EP3030261A4 (en) | Methods of treatment of hpv related diseases | |
EP2951289A4 (en) | PLAZENTAMEMBRANPA PREPARATION AND METHOD FOR THE PRODUCTION AND USE THEREOF |